Physician profile
Manuel A Espinel
NPI 1730399437
$20,169.31
in general payments reported to CMS, 2019-2025
42 companies · $2,772 in 2025
The $2,772 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,485 · 2020: $1,871 · 2021: $3,113 · 2022: $2,980 · 2023: $3,186 · 2024: $2,762 · 2025: $2,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,719.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,647.66 | 2019-2025 | Aveir, Mitraclip, Amplatzer Amulet |
| Astrazeneca Pharmaceuticals LP | $2,128.89 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $1,777.33 | 2019-2024 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $1,680.66 | 2020-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $1,184.33 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,105.02 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $871.03 | 2019-2025 | |
| Esperion Therapeutics, INC. | $850.37 | 2020-2025 | Nexletol, Nexlizet |
| Amgen INC. | $746.29 | 2019-2025 | Otezla, Repatha, Repatha |
| Boston Scientific Corporation | $506.97 | 2019-2023 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $482.40 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $449.41 | 2019-2025 | Eliquis |
| Medtronic, INC. | $448.26 | 2023-2025 | Signia, Ligasure, Intellis Adaptivestim |
| Amarin Pharma, INC. | $409.41 | 2019-2022 | |
| Silk Road Medical, INC. | $338.38 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Espinel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.